FDA Approved Lamlique Oral Suspension
The new liquid medication provides a treatment option for patients with epilepsy and bipolar I disorder.
Updated on Sept. 28, 2026 in Substance Abuse
Live Poll
Do you trust that new liquid medication formats significantly improve the treatment experience for patients?
The FDA has approved Lamlique, a ready-to-use oral suspension formulation of lamotrigine for patients aged 2 years and older. The medication is indicated for specific seizure types, including Lennox-Gastaut syndrome, and for the maintenance treatment of bipolar I disorder.
Why it matters
This approval introduces a liquid alternative for patients who require flexible dosing or struggle with solid medication forms. The suspension offers added convenience by requiring no compounding or refrigeration.
Lamlique is available in concentrations of 5 mg/mL and 25 mg/mL for patients as young as 2 years old. Clinical data indicates a 1 in 500 rate of suicidal thoughts or actions associated with the drug.
The players
Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
The details
Lamlique functions as an adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures, while also serving as maintenance treatment for adult bipolar I disorder. The medication works by lengthening the duration between mood episodes in bipolar patients.
Timeline
September 28, 2026: FDA approved the Lamlique oral suspension.
End of 2026: The medication is expected to be available for use.
Health Landscape
This development aligns with the regulatory trend of prioritizing specialized delivery methods for patients with chronic neurological conditions. It builds upon the established FDA drug approval process for neurological conditions by improving accessibility for patients who have difficulty with pills.
Patients who struggle with traditional tablets can now utilize this liquid suspension, which simplifies daily administration by removing the need for refrigeration or pharmacy compounding. Those starting the medication should consult their doctor regarding the 1 in 500 risk of suicidal thoughts.
The takeaway
This liquid formulation significantly improves medication accessibility for children and adults who cannot swallow solid pills. Patients should maintain open communication with their neurologists or psychiatrists to monitor for mood-related side effects once the drug becomes available.
What happens next
Lamlique is scheduled to hit the market by the end of 2026, when pharmacists and healthcare providers will begin managing supply and prescribing for pediatric and adult patients.
Further reading
Learn more about advancements in Substance Abuse treatments and FDA clinical guidance.
Live Poll
Do you trust that new liquid medication formats significantly improve the treatment experience for patients?
